Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael E Shy, MD
University of Iowa
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Axon Clinical, S.R.O.
Prague, Prague, Czechia
- Fondazione Irccs Istituto Neurologico "carlo Besta"
Milan, Milano, Italy
- University College of London
London, London, United Kingdom
- University of Colorado
Aurora, Colorado, United States
- University of Miami
Coral Gables, Florida, United States
- University of Iowa
Iowa City, Iowa, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Hassman Research Institute
Berlin, New Jersey, United States
- University of Rochester
Rochester, New York, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Jan 2022
- Primary completion
- 12 Oct 2024
- Completion
- 1 Jun 2026
- Last update posted
- 9 Jun 2026
- Registered enrollment
- 56
- Registry id
- NCT05397665
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.